Winrevair is the first FDA-approved activin signaling inhibitor therapy for pulmonary arterial hypertension.
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours